Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philip Jones

Showing results (201-210 of 226) with videos related to

Pageof 23
Sort By:
Cancer Research|March 5, 2015
Genetic events that limit the efficacy of MEK and RTK inhibitor therapies in a mouse model of KRAS-driven pancreatic cancerPiergiorgio Pettazzoni, Andrea Viale, Parantu Shah, et al.
Circulation. Heart Failure|October 18, 2024
Metabolic Effects of the SGLT2 Inhibitor Dapagliflozin in Heart Failure Across the Spectrum of Ejection FractionSenthil Selvaraj, Shachi Patel, Andrew J Sauer, et al.
Nature Medicine|January 19, 2016
Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitorsYi Du, Hirohito Yamaguchi, Yongkun Wei, et al.
Journal of Medicinal Chemistry|October 13, 2021
Discovery of 6-[(3<i>S</i>,4<i>S</i>)-4-Amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-3-(2,3-dichlorophenyl)-2-methyl-3,4-dihydropyrimidin-4-one (IACS-15414), a Potent and Orally Bioavailable SHP2 InhibitorBarbara Czako, Yuting Sun, Timothy McAfoos, et al.
Nature Medicine|October 7, 2016
Corrigendum: Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitorsYi Du, Hirohito Yamaguchi, Yongkun Wei, et al.
Plos Genetics|December 29, 2021
Patient-derived iPSCs link elevated mitochondrial respiratory complex I function to osteosarcoma in Rothmund-Thomson syndromeBrittany E Jewell, An Xu, Dandan Zhu, et al.
Journal of Medicinal Chemistry|August 14, 2020
Discovery of IACS-9439, a Potent, Exquisitely Selective, and Orally Bioavailable Inhibitor of CSF1RBarbara Czako, Joseph R Marszalek, Jason P Burke, et al.
Cancer Research|September 14, 2021
Oxidative Phosphorylation Is a Metabolic Vulnerability in Chemotherapy-Resistant Triple-Negative Breast CancerKurt W Evans, Erkan Yuca, Stephen S Scott, et al.
Journal of Medicinal Chemistry|July 22, 2021
Discovery of IACS-9779 and IACS-70465 as Potent Inhibitors Targeting Indoleamine 2,3-Dioxygenase 1 (IDO1) ApoenzymeMatthew M Hamilton, Faika Mseeh, Timothy J McAfoos, et al.
Lancet (London, England)|December 23, 2014
Genetic diagnosis of developmental disorders in the DDD study: a scalable analysis of genome-wide research dataCaroline F Wright, Tomas W Fitzgerald, Wendy D Jones, et al.
Pageof 23

Showing results (201-210 of 226) with videos related to

Sort By:
Pageof 23
Cancer Research|March 5, 2015
Genetic events that limit the efficacy of MEK and RTK inhibitor therapies in a mouse model of KRAS-driven pancreatic cancerPiergiorgio Pettazzoni, Andrea Viale, Parantu Shah, et al.
Circulation. Heart Failure|October 18, 2024
Metabolic Effects of the SGLT2 Inhibitor Dapagliflozin in Heart Failure Across the Spectrum of Ejection FractionSenthil Selvaraj, Shachi Patel, Andrew J Sauer, et al.
Nature Medicine|January 19, 2016
Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitorsYi Du, Hirohito Yamaguchi, Yongkun Wei, et al.
Journal of Medicinal Chemistry|October 13, 2021
Discovery of 6-[(3<i>S</i>,4<i>S</i>)-4-Amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-3-(2,3-dichlorophenyl)-2-methyl-3,4-dihydropyrimidin-4-one (IACS-15414), a Potent and Orally Bioavailable SHP2 InhibitorBarbara Czako, Yuting Sun, Timothy McAfoos, et al.
Nature Medicine|October 7, 2016
Corrigendum: Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitorsYi Du, Hirohito Yamaguchi, Yongkun Wei, et al.
Plos Genetics|December 29, 2021
Patient-derived iPSCs link elevated mitochondrial respiratory complex I function to osteosarcoma in Rothmund-Thomson syndromeBrittany E Jewell, An Xu, Dandan Zhu, et al.
Journal of Medicinal Chemistry|August 14, 2020
Discovery of IACS-9439, a Potent, Exquisitely Selective, and Orally Bioavailable Inhibitor of CSF1RBarbara Czako, Joseph R Marszalek, Jason P Burke, et al.
Cancer Research|September 14, 2021
Oxidative Phosphorylation Is a Metabolic Vulnerability in Chemotherapy-Resistant Triple-Negative Breast CancerKurt W Evans, Erkan Yuca, Stephen S Scott, et al.
Journal of Medicinal Chemistry|July 22, 2021
Discovery of IACS-9779 and IACS-70465 as Potent Inhibitors Targeting Indoleamine 2,3-Dioxygenase 1 (IDO1) ApoenzymeMatthew M Hamilton, Faika Mseeh, Timothy J McAfoos, et al.
Lancet (London, England)|December 23, 2014
Genetic diagnosis of developmental disorders in the DDD study: a scalable analysis of genome-wide research dataCaroline F Wright, Tomas W Fitzgerald, Wendy D Jones, et al.
Pageof 23